Physician profile
Glenn Davis
NPI 1497757298
$5,890.26
in general payments reported to CMS, 2019-2025
40 companies · $541 in 2025
The $541 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,060 · 2020: $217 · 2021: $1,482 · 2022: $1,030 · 2023: $1,131 · 2024: $429 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,100.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,151.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,043.49 | 2021-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $434.17 | 2019-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $420.46 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $407.87 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $346.27 | 2019-2023 | |
| Pfizer INC. | $253.97 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $216.42 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $148.93 | 2022-2025 | Rexulti |
| Glaxosmithkline, LLC. | $139.95 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.75 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $131.51 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $105.14 | 2021-2022 | |
| Amgen INC. | $95.59 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.69 | 2021-2025 | Jardiance |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.